Error
  • The template for this display is not available. Please contact a Site administrator.

Drug Allergy

Review and collect the all data available in the literature (Pub Med, the Cochrane Library, Embase, National Institutes of Health ) about the incidence, pathogenesis, diagnosis and management of hypersensitivity reactions to AEDs in children.
-State recommendations on diagnosis and management, based on available evidences data and on panel consensus experts in the field of hypersensitivity reactions to AEDs in children

Chair: Marina Atanaskovic-Markovic
Secretary: Francesca Mori
Fifteen years ago, a Task force of the ENDA (European Network for Drug Allergy), the core part of the EAACI drug allergy interest group published a paper on general considerations on drug provocation tests (DPT). Since 2003, a lot of studies have been published on DPT, considered the Gold Standard diagnostic procedure for determination of the culprit drug in patients with a suspected drug allergy. An update is urgently needed and more detailed recommendations are required in order to harmonize our methods across Europe. Specific areas such as risk stratification of patients, indications and contra-indications for DPT in adults and children, dosages of test preparations, number of doses and time intervals have to be discussed. Finally, since the  the value of desensitization procedures has been demonstrated during the last 10 years, the differences between DPT and desensitization procedures have to be analyzed and explained.

Chair: Annick Barbaud 
Secretary: Lene Heise Garvey
pill
Chemotherapeutic drugs are widely used in the treatment of a variety of cancers. Some chemotherapeutic drugs are also called antineoplastic when they are designed to prevent or inhibit the development of a tumor. The use of these drugs is associated with secondary effects that range from mild gastrointestinal symptoms, cough, transient rash and itching, to life-threatening reactions such as severe cytopenia and anaphylaxis. Hence there is an increased need to improve the diagnostic tools and management of hypersensitivity reactions (HRSs) to antineoplastic agents.
This Task Force, composed by specialists in the field, will focus on compiling data on incidence, pathophysiology, clinical symptoms, diagnostic tools and management of HRSs to antineoplastic agents (with a particular focus on indications and limits to desensitization procedures) to support clinicians in the diagnosis and treatment.

Interest group: Drug Allergy
Chair: Mauro Pagani
Secretary: Sevim Bavbek

Relevant literature:

- Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs

- Castells MC. Hypersensitivity to antineoplastic agents

- Syrigou E. et al. Hypersensitivity reactions to antineoplastic agents: an overview
pill
Gastrointestinal diseases are frequently associated with an inflammation of the gastrointestinal tract. In these types of diseases, anti-acid drugs which decrease acidic secretions are widely used to alleviate the symptoms. H2 receptor antagonists (2RA), for example, make the cells (parietal cells) responsible for acid secretion less responsive to stimuli thus decreasing acidity, while proton pump inhibitors (PPIs) block the final step in gastric acid secretion, halting all acid secretion.
PPIs are usually tolerated by patients with a low risk of side effects. However, serious adverse non allergic (cytopenia, vasculitis, acute interstitial nephritis, hepatitis, cutaneous lupus erythematosus) and allergic reactions have been reported in some cases. In the last years, the number of reported hypersensitivity, or allergic reactions, to PPIs has increased. One hypothesis is that this increase is correlated to the increased consumption of the drug, although this is not yet proven.
To address the increase of hypersensitivity or allergic reactions to PPIs, this task force will evaluate in detail the recent data related to incidence, immune mechanisms (underlying immediate and non-immediate reactions to PPIs, clinical symptoms, and diagnostic approaches in vivo (skin testing and drug provocation tests) and in vitro (lenfosit activation test). Ultimately, the aim of the task force is to establish a comprehensive review that will support diagnosis, treatment and prevention of PPI hypersensitivity.


Interest Group: Drug Allergy
Chair: Sevim Bavbek
Secretary: Patrizia Bonadonna

Relevant literature:

- Özdemir S. et al. Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due to proton pump inhibitors

- Untersmayr E. Acid suppression therapy and allergic reactions

- DeMuth K. et al. Relationship between treatment with antacid medication and the prevalence of food allergy in children